5 questions about the FDA's fast-track push for psychedelic treatments
The Food and Drug Administration awarded priority review vouchers to three companies developing psychedelic-based treatments for mental health conditions -- two studying psilocybin for hard-to-treat depression and one studying methylone, an MDMA-related drug, for PTSD.
Original Source
Read the full article at Washingtontimes →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.